Therefore, I pray you, lead me to the caskets To try my fortune. By this scimitar That slew the Sophy and a Persian prince That won three fields of Sultan Solyman, I would outstare the sternest eyes that look, Outbrave the heart most daring on the earth . . . .
Prince of Morocco, Merchant of Venice, William Shakespeare
Scimitar syndrome refers to the anomalous connection of the right lower pulmonary vein or all the right-sided pulmonary veins to the inferior vena cava. This is often associated with right lung hypoplasia and systemic arterial supply to segments of the right lung, most commonly the lower lobe. The broad clinical spectrum of scimitar syndrome was eloquently summarized by Frye as 'normal right lung or partial agenesis thereof; normal heart or dextroposition thereof; absence or possible presence of an anomalous systemic artery to the right lung; and absence or presence of an associated atrial septal defect' (ASD). 1 The co-occurrence of these findings was first reported almost 200 years ago, 2,3 with the first pre-mortem diagnoses described in 1949; the diagnosis was suggested when 'conventional frontal roeantenogram of the chest revealed asymmetry. . ..the heart was shifted slightly to the right and its right border appeared prominent. Curving downward through the right lower lung field was a band-like shadow which widened gradually as it descended, paralleling the right atrial border. It then turned inward, becoming obscured at the right costo-phrenic angle. . ..'. 4 Halasz and colleagues mentioned that the X-ray appearance resembled a scimitar (Figure 1 ), a curved, Middle Eastern sword which often widens towards its pointed end, in 1956. 5 The term 'scimitar syndrome' was introduced in 1960, 6 a brilliant example of effective medical branding.
Scimitar syndrome is uncommon, accounting for only 3-5% of cases of partial anomalous venous return, and most previous reports describe the experience of a single centre, with small sample size and uncertain generalizability. The authors, notably the first author, has dedicated himself to advancing our understanding of this rare disease. Dr Vida edited a recently published comprehensive monograph on scimitar syndrome, 7 which we highly recommend as a reference, and he has previously assembled several multi-centred cohorts. [8] [9] [10] The study by Vida et al. in this issue of the journal, however, dwarfs earlier efforts in scale, with data on almost 500 patients with scimitar syndrome seen at 51 centres. 11 This global collaboration exemplifies the benefits and necessity of sharing data for advancing the understanding of rare diseases. Median hospital volume was low, 6 cases, with only a quarter of hospitals contributing >11 patients. The consortium was comprised predominantly of paediatric centres, and consequently the study sample was heavily tilted towards younger patients, with 58% <1 year old, while only 19% were > _10 years old. Half the patients had an associated ASD, and 71% had right lung hypoplasia. Complex congenital heart disease (CHD) coexisted in 21% of the overall study sample. Most, almost threequarters, of the patients were symptomatic. The risk of post-surgical mortality, both in hospital and during follow-up, increased with younger age, and the presence of concomitant complex CHD and pulmonary hypertension. Age is an especially important confounder as disease severity strongly parallels age at diagnosis. Previously reports have delineated distinct 'infantile' and 'adult' forms of scimitar syndrome. [12] [13] [14] [15] In line with previous studies, those who presented as neonates in the current report were more often symptomatic, had a high burden of associated complex CHD, were more likely to have pulmonary hypertension, had a higher prevalence of associated systemic arterial supply to the right lung, and had more severe right lung hypoplasia. Thus, the high risk of adverse outcomes in neonates more probably reflects disease severity rather than age itself. The exception, and perhaps the key takeaway from this study, is the high incidence of stenosis or occlusion of the surgically constructed pulmonary venous drainage. The risk was particularly high in neonates (33%), possibly in part due to disease severity, but probably mainly related to body size. While lower, the risk of postoperative obstruction was substantial in children (20%) and adolescents/adults (14%). This has been a consistent finding after scimitar repair in the published literature. 9, 14 These sobering figures should
give pause to clinicians considering surgical intervention for asymptomatic patients.
As noted by the authors, severe clinical disease or associated complex CHD often compels management decisions in neonates, while the decision to perform surgery in older children and adults is frequently fraught with ambiguity. Unfortunately, the current data do not provide substantial insight into decision-making for this latter group, largely because adolescents and adults made up only a small subset of the study sample. Current clinical guidelines for the care of adults with CHD do not comment specifically on scimitar syndrome or other forms of partial anomalous pulmonary venous return. 16, 17 While there are sometimes idiosyncratic reasons to consider surgery, such as recurrent infection, in most cases the decision rests on the balance between the chronic effects of the right heart volume load and operative risk, both acute and long term. The authors propose a treatment algorithm, based on their considerable clinical experience and expertise, to guide surgical referral for isolated scimitar syndrome. They rightly emphasize that, given the high incidence of surgical complications, surgery should be reserved for patients with notable shunt with pulmonary circulatory overload, defined in the Discussion as a Qp:Qs >1.5:1. Others have suggested a cut-off Qp:Qs of at least 2:1.
14 While we agree with the overarching message, we would tend to think the latter figure is more likely to approximate the appropriate balance between risk and benefit. It stands to reason that our threshold to intervene in scimitar syndrome should be higher than that for isolated ASD in the context of unquestionably greater risk and presumably equivalent benefit. In any case, however, we rarely depend on Qp:Qs as a primary variable in contemporary clinical decision-making. Qp:Qs is dynamic and is also often estimated imprecisely. A more comprehensive consideration of right-sided volume overload, with integration of right heart volumes and function as well as Qp:Qs, should provide a firmer foundation upon which to make a decision. The current study has two considerable strengths: large sample size and breadth of participating centres. There are also several limitations beyond the usual pitfalls of retrospective observational research (e.g. bias by indication and unmeasured confounding); however, that should be considered as readers integrate these data into their practice. First, there was a wide range of disease severity and heterogeneity of clinical contexts. While the authors do a commendable job of reporting the implications of various key variables, it is impossible to tease out the relevance of these findings for a specific patient in whom the best clinical approach is unclear, say an asymptomatic 42-year-old man with isolated scimitar syndrome, mild right lung hypoplasia, mean pulmonary artery pressure of 26 mmHg, and a Qp:Qs of 1.9. Secondly, as is often the case in large multi-centred studies, a degree of detail and nuance available in smaller singlecentre studies has been sacrificed. For example, the overall breakdown of surgical approach is provided, but there is no discussion of clinical characteristics associated with a particular approach. The relationship of surgical approach to the risk of complications is also not presented; the authors have previously reported data from a smaller cohort on this question, 9 but it would be useful to understand whether those findings are generalizable to this larger patient sample. It would also be interesting to analyse whether surgical volume, whether for scimitar syndrome repair or repair of any partial anomalous pulmonary venous return, is associated with outcomes. Some key pathophysiological variables are also only characterized incompletely. Pulmonary hypertension, for example, was defined based on mean pulmonary artery pressure by catheterization or a transthoracic echocardiogram suggesting systolic pulmonary pressure >50% systemic, without data on pulmonary vascular resistance. Clinical decisions depend heavily on whether pulmonary hypertension is due to elevated pulmonary vascular resistance or to shunt-related high flow. In summary, the results of this large series of patients with scimitar syndrome confirm that neonates have a dramatically distinct clinical presentation compared with older patients, further highlight the key role of associated clinical characteristics in defining prognosis, and provide a more precise estimate of the high risk of scimitar vein obstruction after surgical repair. This report represents a victorious battle in an ongoing crusade to understand scimitar syndrome and thereby improve the outcomes for patients born with this rare disease.
